Hong C Z, Hsueh T C
Department of Physical Medicine and Rehabilitation, University of California, Irvine, USA.
Arch Phys Med Rehabil. 1996 Nov;77(11):1161-6. doi: 10.1016/s0003-9993(96)90141-0.
To compare responses to trigger point (TrP) injection between patients having both myofascial pain syndrome (MPS) caused by active TrPs and fibromyalgia syndrome (FMS) and patients with MPS due to TrPs but without FMS.
Prospective design blinded measurement, before- after trial.
A pain control medical clinic.
Group 1: MPS + FMS; Group 2: MPS only. All patients (9 in each group) had active TrPs in the upper trapezius muscle.
Myofascial TrP injection with 0.5% xylocaine.
Subjective pain intensity (PI), pain threshold (PT), and range of motion (ROM) were assessed before, immediately after, and 2 weeks after TrP injection.
In a comparison of preinjection measures to immediate postinjection measures, only ROM was significantly improved (p < .05) in Group 1 patients; all three parameters were significantly improved (p < .05) in the Group 2 patients who had only MPS. Two weeks after injection, both groups showed significant improvement (p < .05) in all three measured parameters as compared to preinjection measurements. In a comparison of the two groups, the immediate effectiveness of TrP injection was significantly less (p < .05) in Group 1 than in Group 2 for all three parameters. Two weeks after injection, the degree of improvement in PT or ROM (but not PI) was not significantly different between two groups. Postinjection soreness (different from myofascial pain) was more severe, developed sooner, and lasted longer in Group 1 than in Group 2.
Trigger point injection is a valuable procedure for pain relief for patients in both group. Patients with FMS are likely to experience significant but delayed and attenuated pain relief following injection of their active TrPs compared to myofascial pain patients with similar TrPs but without FMS. Also, FMS patients are likely to experience significantly more postinjection soreness for a longer period of time.
比较由活跃触发点(TrP)引起的肌筋膜疼痛综合征(MPS)合并纤维肌痛综合征(FMS)的患者与仅有由TrP引起的MPS但无FMS的患者对触发点注射的反应。
前瞻性设计、盲法测量、前后试验。
一家疼痛控制医疗诊所。
第1组:MPS + FMS;第2组:仅MPS。所有患者(每组9名)在上斜方肌均有活跃TrP。
用0.5%利多卡因进行肌筋膜TrP注射。
在TrP注射前、注射后即刻以及注射后2周评估主观疼痛强度(PI)、疼痛阈值(PT)和活动范围(ROM)。
在比较注射前与注射后即刻的测量结果时,第1组患者中只有ROM有显著改善(p < 0.05);仅有MPS的第2组患者的所有三个参数均有显著改善(p < 0.05)。注射后2周,与注射前测量结果相比,两组的所有三个测量参数均有显著改善(p < 0.05)。在两组比较中,对于所有三个参数,TrP注射的即刻有效性在第1组显著低于第2组(p < 0.05)。注射后2周,两组之间PT或ROM(但不是PI)的改善程度无显著差异。注射后酸痛(与肌筋膜疼痛不同)在第1组比第2组更严重、出现更早且持续时间更长。
触发点注射对两组患者缓解疼痛都是一种有价值的方法。与具有相似TrP但无FMS的肌筋膜疼痛患者相比,FMS患者在注射其活跃TrP后可能会经历显著但延迟且减弱的疼痛缓解。此外,FMS患者可能在更长时间内经历显著更多的注射后酸痛。